NEW YORK (Thomson Financial) - Ziopharm Oncology Inc. Monday reported a
positive result in its Phase II study for ZIO-201, which treats soft tissue and
bone sarcomas.
The New York-based pharmaceutical company said 48% of its evaluable patients
had stable disease or better during the study, and that progression free
survival rates compared favorably to rates reported for historical controls with
fewer serious toxicities.
Shares of Ziopharm closed Friday at $3.54.
Ryan Vlastelica
rv/pc
COPYRIGHT
Copyright Thomson Financial News Limited 2007. All rights reserved.
The copying, republication or redistribution of Thomson Financial News Content,
including by framing or similar means, is expressly prohibited without the prior
written consent of Thomson Financial News.
|